Literature DB >> 10988349

Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor.

D Wu1, W Eberlein, K Rudolf, W Engel, G Hallermayer, H Doods.   

Abstract

The present study was performed in order to characterise calcitonin gene-related peptide (CGRP) receptor subtypes in rat left atrium and vas deferens by using [R-(R*, S*)]-N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]pentyl ]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1, 4-dihydro-2-oxo-3(2H)-quinazolinyl)-,1-Piperidinecarboxamide (BIBN4096BS), a novel CGRP receptor antagonist. When CGRP was used as an agonist, BIBN4096BS exhibited an almost 10-fold higher affinity for CGRP receptors in rat left atrium compared to those in the vas deferens, indicating that CGRP acts through different CGRP receptor subtypes in these two tissues. In addition, BIBN4096BS was almost 10-fold more potent in antagonizing [Cys(Et)(2,7)]hCGRPalpha and human adrenomedullin-induced responses than CGRP-induced responses in rat vas deferens. This might indicate receptor heterogeneity in rat vas deferens. Accordingly, the present work provides first experimental evidence that the rat vas deferens contains two CGRP-like receptor subtypes. Namely, the CGRP(2) receptor and a "novel" receptor that possesses low efficacy for CGRP and that is selectively stimulated by [Cys(Et)(2,7)]hCGRP or adrenomedullin and which can be blocked with high affinity by BIBN4096BS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10988349     DOI: 10.1016/s0014-2999(00)00407-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 2.  Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.

Authors:  Lars Edvinsson
Journal:  CNS Drug Rev       Date:  2005

3.  Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat.

Authors:  Kenneth A Petersen; Steffen Birk; Henri Doods; Lars Edvinsson; Jes Olesen
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

Review 4.  Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.

Authors:  Linde Buntinx; Steve Vermeersch; Jan de Hoon
Journal:  Br J Clin Pharmacol       Date:  2015-10-06       Impact factor: 4.335

5.  Characterization and effects on cAMP accumulation of adrenomedullin and calcitonin gene-related peptide (CGRP) receptors in dissociated rat spinal cord cell culture.

Authors:  Mohammad A Takhshid; David R Poyner; Jean-Guy Chabot; Alain Fournier; Weiya Ma; Wen-Hua Zheng; Ali A Owji; Remi Quirion
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

6.  Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Authors:  Kapil Kapoor; Udayasankar Arulmani; Jan P C Heiligers; Ingrid M Garrelds; Edwin W Willems; Henri Doods; Carlos M Villalón; Pramod R Saxena
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 8.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

9.  Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries.

Authors:  Majid Sheykhzade; Henrik Lind; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2004-10-11       Impact factor: 8.739

10.  Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines.

Authors:  Tejal Choksi; Debbie L Hay; Stephen Legon; David R Poyner; Stefanie Hagner; Stephen R Bloom; David M Smith
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.